Albany Molecular Research, Inc. (NASDAQ:AMRI)

There are currently 4500 AMRI shares in my "fund" with break-even of around 3.75 USD.
http://caps.fool.com/Blogs/fund-trades/678775.

Langer

Thanks Langerzans

How could anyone not be excited about a company called Albany Molecular Research? I mean it's Albany, come on! The Real World Albany? Real Housewives of Albany? No?

Fine then. We'll try and look at the company on its merits instead. When I see a stock carving out new all-time lows with no sign of a plateau I start looking for reasons why the company might be going out of business, and with AMR I'm just not finding them. The company has separate and solid revenue streams from Allegra royalties and outsourced contract research. Quarterly revenues and cash reserves have been stable for at least a year, dating back to when the share price was over 6. In the midst of the 2009 decline, the stock traded at 8. Meanwhile, debt remains low and manageable.

The company projects continuing stable revenues and expenses through the end of the year. Despite the instability in the economy and the markets, I have not noted a significant tendency of large or small pharmaceutical companies and biotechs to reduce their research budgets. AMR certainly seems more likely to survive the current decline than the one of early 2009, which they weathered well.

My advisor brought this stock to my attention. Ever since the tech bubble burst back in 2000 this stock has been trading flat or trending down. It made a few attempts to rise but has given the impression that it can't go up. The recent quiet action along with quiet volume and shakeout from the $10 level is a great time to buy. I think this stock has a large rise in its future which could take years to develop. All I know is buy now when it has turned very quiet and has now been under accumulation for the better part of 10 years. Be patient and I believe you will be rewarded.

This company is not at all well run. It does not take care of its employees. Instead, it uses them and throws them away resulting in excessive turn over. Communication within the company is highly controlled and honesty will result in retaliation. This is all easily verifiable. Ask any of the literally hundreds of people who no long work for them. This is a signal of institional sickness and the buck falls at the very top...but money keeps some people in control.

EPS 08: .62 p/e 13.1
EPS 09: .05 p/e 162.8
EPS 10: .13 p/e 62.62

Fundamentally speaking, this is a sell

Profitable pharmacy research and development company with good valuation ratios and low debt. Also, I feel the chart has already reached the bottom.

L/R D/E ratio's look good.

BUYING AT 5 PER SHARE, stock is valued in my fair value estimates at 5.40 a share i expect movement at this price in late summer.

good company worth 5 or more a share.

On a strictly technical basis, my magic charts say this will outperform the S&P

Albany Molecular Research is another case of the slow and steady turtle executing with a solid management team to deliver results. The past four quarters have shown rather large earnings beats and at 31 times earnings and with $3.14 per share in cash I think they can solidly deliver 15% stock price appreciation per annum. The price to book valuation is in-line if not just below the sector average and the long-term technicals show an ascending triangle that wants to break hgiher above $18. All signs pointing higher.

Nero

Sagetrade

new

Growing by pharmaceutical development and licensing or partnership with large pharma corps.

sc score 10, good earning forecast

Lagging CRO sector, plus participation in near term drug discovery candidates

a VALUE PROPOSITION